inHEART develops AI-driven 3D cardiac models — described as digital twins of the heart — used by electrophysiologists and cardiologists to plan ablation procedures and screen for risks like heart failure, sudden cardiac death, and cardio-embolic stroke. Founded in 2017 in Pessac, France, by Maxime Sermesant, Hubert Cochet, and Pierre Jais, the company also operates a US subsidiary in Boston.
Clinicians send anonymized CT or MRI scans to inHEART's cloud service, where proprietary segmentation algorithms build a detailed, interactive 3D model of the patient's heart within a 24-hour turnaround. The company received FDA 510(k) clearance for its AI segmentation software and has raised $15.2 million across two rounds, including an $11 million Series A co-led by Vesalius Biocapital IV and Elaia Partners to commercialize its ablation-planning tools.
inHEART sells to hospitals and cardiac catheterization labs rather than individual patients or consumers, and pricing runs through direct hospital contracts rather than a published price list. A live demo of the modeling workflow is available at demo.inheartmedical.com for clinicians evaluating the platform.
